FINWIRES · TerminalLIVE
FINWIRES

ANZリサーチによると、原油価格ショックの影響でニュージーランドの消費者信頼感は3年ぶりの低水準に近づいている。

By

-- ANZリサーチは金曜日、ニュージーランドの消費者信頼感指数が4月に約3年ぶりの低水準に落ち込んだと発表した。これは、迫りくる原油価格ショックが経済見通し全般への懸念と小売業者の下振れリスクを高めたためだ。 ANZ-ロイ・モーガン消費者信頼感指数は、3月の91.3から4月には11ポイント低下し、80.3となった。この指数は、中東紛争の勃発と世界的な燃料価格の高騰以来、過去2ヶ月間で20ポイント低下している。 インフレ期待はさらに約1ポイント上昇し、6.6%となった。「大型家庭用品を購入するのに良い時期だ」と考える世帯の割合は11ポイント低下し、マイナス25となり、2024年9月以来の低水準となった。 同社は、原油価格ショックが家計所得に大きな影響を与えるには時期尚早であり、今回の低下はむしろ生活費の上昇と、小売業者の間で将来の活動水準に対する警戒感が高まっていることを反映していると述べた。 しかし、現在2022年と2023年の水準にある消費者信頼感は、ガソリン価格の高騰が家計を圧迫しているため、「明らかに悪化している」。 消費者のインフレ期待は価格設定に直接影響しないため、中央銀行の主要な関心事ではないものの、消費者のインフレ期待6.6%と企業の賃金期待2.5%との乖離が拡大している、と同行は付け加えた。

Related Articles

Asia

Telix Says Marketing Authorization Application for Glioma Imaging Candidate Accepted for Review in Europe; Shares Up 3%

Telix Pharmaceuticals (ASX:TLX) said Friday its marketing authorization application filed in Europe for TLX101-Px, its glioma imaging candidate, has been validated and accepted for review, moving into a 210-day active assessment phase.In a statement, the company said it is seeking a broad clinical label, reflective of current clinical practice guidelines, with national marketing authorizations expected to follow shortly after a positive outcome at day 210.The company said it aims to expand patient access to advanced imaging that can distinguish progressive or recurrent glioma from treatment-related changes in both adults and children, with potential for additional future indications.TLX101-Px is also being developed as a patient selection and response assessment tool for Telix's glioblastoma therapy candidate TLX101-Tx, which has been granted orphan drug designation in Europe and the US, per the statement.The phase 3 IPAX-BrIGHT trial of TLX101-Tx in patients with recurrent glioblastoma has started patient dosing internationally and is launching in multiple European countries, the company said.Telix Pharmaceuticals' shares were up 3% in recent Friday trade.

$ASX:TLX
Asia

Zozo's Profit Climbs 6% in Fiscal Year 2025

Zozo's (TYO:3092) profit attributable to owners of the parent rose 5.7% to 47.93 billion yen for the fiscal year 2025 from 45.35 billion yen a year earlier.The shopping mall operator's basic earnings per share increased to 54.11 yen from 50.90 yen a year ago, according to a Tokyo bourse filing on Thursday.Net sales climbed 7.2% to 228.37 billion yen for the full year ended March 31 from 213.13 billion yen in the prior year.The company declared a year-end dividend of 20 yen per share, payable from June 11.For the fiscal year 2026, the company expects attributable profit of 49.7 billion yen, EPS of 56.20 yen, and net sales of 241.9 billion yen.Zozo plans to pay interim and year-end dividends of 20 yen per share each for the year, which is higher than the amount in the year-ago period.

$TYO:3092
Asia

EML Payments Says Regulators Extend Date for Implementation of Required Guarantee Structure

EML Payments (ASX:EML) said the Australian Prudential Regulation Authority (APRA) and Reserve Bank of Australia (RBA) agreed to extend the date for implementation of the required authorized deposit-taking institution guarantee structure, subject to EML Payment Solutions showing "satisfactory progress" towards obtaining the guarantee via periodic reporting, according to a Friday Australian bourse filing.EML Payment Solutions is engaging with several domestic and international financial institutions, as well as legal advisors and trustee service providers, to design the required guarantee structure.The regulators had earlier said that they require the firm to obtain a guarantee from an authorized deposit-taking institution in respect of stored value liabilities for certain EML Payment Solutions programs by Thursday.

$ASX:EML